# Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

> **NCT00387127** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 67 (actual)

## Conditions studied

- Neoplasms, Head and Neck

## Interventions

- **DRUG:** Lapatinib oral tablets
- **DRUG:** radiotherapy
- **DRUG:** cisplatin chemotherapy

## Key facts

- **NCT ID:** NCT00387127
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-06
- **Final completion:** 2014-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387127, "Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00387127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*